{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:28:30Z","timestamp":1780406910608,"version":"3.54.1"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>\n                    In this study, we aimed to test whether prognostic biomarkers can achieve a clinically relevant stratification of patients with stage I ovarian clear cell carcinoma (OCCC) and to survey the expression of 10 selected actionable targets (theranostic biomarkers) in stage II to IV cases. From the population-based Alberta Ovarian Tumor Type study, 160 samples of OCCC were evaluated by immunohistochemistry and\/or silver-enhanced in situ hybridization for the status of 5 prognostic (p53, p16, IGF2BP3, CCNE1, FOLR1) and 10 theranostic biomarkers (ALK, BRAF V600E, ERBB2, ER, MET, MMR, PR, ROS1, NTRK1-3, VEGFR2). Kaplan-Meier survival analyses were performed. Cases with abnormal p53 or combined p16\/IFG2BP3 abnormal expression identified a small subset of patients (6\/54 cases) with stage I OCCC with an aggressive course (5-yr ovarian cancer-specific survival of 33.3%, compared with 91.5% in the other stage I cases). Among theranostic targets,\n                    <jats:italic toggle=\"yes\">ERBB2<\/jats:italic>\n                    amplification was present in 11\/158 (7%) of OCCC, while MET was ubiquitously expressed in OCCC similar to a variety of normal control tissues. ER\/PR showed a low prevalence of expression. No abnormal expression was detected for any of the other targets. We propose a combination of 3 biomarkers (p53, p16, IGF2BP3) to predict prognosis and the potential need for adjuvant therapy for patients with stage I OCCC. This finding requires replication in larger cohorts. In addition, OCCC could be tested for\n                    <jats:italic toggle=\"yes\">ERBB2<\/jats:italic>\n                    amplification for inclusion in gynecological basket trials targeting this alteration.\n                  <\/jats:p>","DOI":"10.1097\/pgp.0000000000000780","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T13:21:10Z","timestamp":1616764870000},"page":"168-179","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Katharina","family":"Wiedemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda E.","family":"Kelemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Feil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Anglesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafull","family":"Ghatage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2011.01.005","article-title":"Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010","volume":"121","author":"Anglesio","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/annonc\/mdq383","article-title":"Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers","volume":"22","author":"Swenerton","year":"2011","journal-title":"Ann Oncol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2009.09.029","article-title":"Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications","volume":"116","author":"Kobel","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PGP.0000000000000521","article-title":"Comprehensive surgical staging in stage 1 clear cell and endometrioid ovarian carcinomas: is it necessary?","volume":"38","author":"Padhy","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study","volume":"111","author":"Kobel","year":"2014","journal-title":"Br J Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/modpathol.2016.160","article-title":"CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis","volume":"30","author":"Ayhan","year":"2017","journal-title":"Mod Pathol"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cjp2.109","article-title":"Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study","volume":"4","author":"Rambau","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3389\/fonc.2019.01570","article-title":"Overexpression of IGF2BP3 as a potential oncogene in ovarian clear cell carcinoma","volume":"9","author":"Liu","year":"2019","journal-title":"Front Oncol"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/PAS.0000000000001328","article-title":"p53, Mismatch repair protein, and POLE abnormalities in ovarian clear cell carcinoma: an outcome-based clinicopathologic analysis","volume":"43","author":"Parra-Herran","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","article-title":"Genomics-driven oncology: framework for an emerging paradigm","volume":"31","author":"Garraway","year":"2013","journal-title":"J Clin Oncol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-20250802","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/PAS.0000000000001120","article-title":"ALK is a specific diagnostic marker for inflammatory myofibroblastic tumor of the uterus","volume":"42","author":"Mohammad","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/bjc.2013.126","article-title":"New perspectives on molecular targeted therapy in ovarian clear cell carcinoma","volume":"108","author":"Tan","year":"2013","journal-title":"Br J Cancer"},{"key":"R18-20250802","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site\u2014when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/path.5037","article-title":"Clear cell carcinomas of the ovary and kidney: clarity through genomics","volume":"244","author":"Ji","year":"2018","journal-title":"J Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","article-title":"A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group Study (GOG-254)","volume":"150","author":"Chan","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-18-1244","article-title":"A clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the princess margaret phase II consortium","volume":"24","author":"Lheureux","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/his.12934","article-title":"Significant frequency of MSH2\/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas","volume":"69","author":"Rambau","year":"2016","journal-title":"Histopathology"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"16215","DOI":"10.18632\/oncotarget.3976","article-title":"MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)","volume":"6","author":"Casadevall","year":"2015","journal-title":"Oncotarget"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma","volume":"2","author":"Kobel","year":"2016","journal-title":"J Pathol Clin Res"},{"issue":"suppl 1","key":"R31-20250802","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","article-title":"An immunohistochemical algorithm for ovarian carcinoma typing","volume":"35","author":"Kobel","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/PGP.0000000000000530","article-title":"Ovarian carcinoma histotype: strengths and limitations of integrating morphology with immunohistochemical predictions","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/PAS.0000000000000476","article-title":"morphologic and molecular characteristics of mixed epithelial ovarian cancers","volume":"39","author":"Mackenzie","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"618","DOI":"10.5858\/arpa.2014-0395-CP","article-title":"Template for reporting results of HER2 (ERBB2) biomarker testing of specimens from patients with adenocarcinoma of the stomach or esophagogastric junction","volume":"139","author":"Bartley","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.13704","article-title":"HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation","volume":"73","author":"Koopman","year":"2018","journal-title":"Histopathology"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","article-title":"IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer","volume":"17","author":"Anglesio","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/PGP.0000000000000291","article-title":"immunohistochemical profiling of endometrial serous carcinoma","volume":"36","author":"Chen","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1078-0432.CCR-10-1688","article-title":"Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas","volume":"17","author":"Tan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nat Commun"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","article-title":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","volume":"150","author":"Konstantinopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0b013e3181788546","article-title":"A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary","volume":"33","author":"Kobel","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"R48-20250802","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/PAS.0000000000001432","article-title":"Mismatch repair deficiency in ovarian carcinoma: frequency, causes, and consequences","volume":"44","author":"Leskela","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R49-20250802","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/PGP.0000000000000369","article-title":"Frequent mismatch repair protein deficiency in mixed endometrioid and clear cell carcinoma of the endometrium","volume":"36","author":"Kobel","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"R50-20250802","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1158\/1078-0432.CCR-18-3691","article-title":"survival following chemotherapy in ovarian clear cell carcinoma is not associated with pathological misclassification of tumor histotype","volume":"25","author":"Takenaka","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R51-20250802","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/PAS.0000000000000602","article-title":"Mismatch repair protein expression in clear cell carcinoma of the ovary: incidence and morphologic associations in 109 cases","volume":"40","author":"Bennett","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R52-20250802","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1200\/JOP.19.00773","article-title":"germline and somatic tumor testing in epithelial ovarian cancer: ASCO Guideline Summary","volume":"16","author":"Konstantinopoulos","year":"2020","journal-title":"JCO oncology practice"},{"key":"R53-20250802","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2020.01.002","article-title":"High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy","volume":"98","author":"Wiedemeyer","year":"2020","journal-title":"Hum Pathol"},{"key":"R54-20250802","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/537S63a","article-title":"Perspective: the precision-oncology illusion","volume":"537","author":"Prasad","year":"2016","journal-title":"Nature"},{"key":"R55-20250802","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMsb1607705","article-title":"Limits to personalized cancer medicine","volume":"375","author":"Tannock","year":"2016","journal-title":"N Engl J Med"},{"key":"R56-20250802","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jcp.2006.040030","article-title":"Ovarian clear cell adenocarcinoma: a continuing enigma","volume":"60","author":"Tan","year":"2007","journal-title":"J Clin Pathol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:02:53Z","timestamp":1754161373000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000780","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.21.20178830","asserted-by":"object"}]},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,24]]}}}